217 related articles for article (PubMed ID: 31071376)
21. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
22. Discovery of Small Molecules for the Reversal of T Cell Exhaustion.
Marro BS; Zak J; Zavareh RB; Teijaro JR; Lairson LL; Oldstone MBA
Cell Rep; 2019 Dec; 29(10):3293-3302.e3. PubMed ID: 31801090
[TBL] [Abstract][Full Text] [Related]
23. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.
Nastala CL; Edington HD; McKinney TG; Tahara H; Nalesnik MA; Brunda MJ; Gately MK; Wolf SF; Schreiber RD; Storkus WJ
J Immunol; 1994 Aug; 153(4):1697-706. PubMed ID: 7913943
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis.
Stockfleth E; Bastian M
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):911-918. PubMed ID: 30074409
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
[TBL] [Abstract][Full Text] [Related]
26. Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T cells or macrophages in the tumor-bearing state.
Yamamoto N; Zou JP; Li XF; Takenaka H; Noda S; Fujii T; Ono S; Kobayashi Y; Mukaida N; Matsushima K
J Immunol; 1995 Mar; 154(5):2281-90. PubMed ID: 7868900
[TBL] [Abstract][Full Text] [Related]
27. HIV type 1 inhibition by protein kinase C modulatory compounds.
Warrilow D; Gardner J; Darnell GA; Suhrbier A; Harrich D
AIDS Res Hum Retroviruses; 2006 Sep; 22(9):854-64. PubMed ID: 16989610
[TBL] [Abstract][Full Text] [Related]
28. Immunochemotherapy mediated by thermosponge nanoparticles for synergistic anti-tumor effects.
Zhao Y; Song Q; Yin Y; Wu T; Hu X; Gao X; Li G; Tan S; Zhang Z
J Control Release; 2018 Jan; 269():322-336. PubMed ID: 29174440
[TBL] [Abstract][Full Text] [Related]
29. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.
Gupta AK; Paquet M
J Cutan Med Surg; 2013; 17(3):173-9. PubMed ID: 23673300
[TBL] [Abstract][Full Text] [Related]
30. Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes.
Rosenberg SA; Schwarz SL; Spiess PJ
J Natl Cancer Inst; 1988 Nov; 80(17):1393-7. PubMed ID: 3262772
[TBL] [Abstract][Full Text] [Related]
31. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
32. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
[TBL] [Abstract][Full Text] [Related]
33. Combined treatment with interleukin-18 and low-dose interleukin-2 induced regression of a murine sarcoma and memory response.
Son YI; Dallal RM; Lotze MT
J Immunother; 2003; 26(3):234-40. PubMed ID: 12806277
[TBL] [Abstract][Full Text] [Related]
34. Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation.
Li SY; Liu Y; Xu CF; Shen S; Sun R; Du XJ; Xia JX; Zhu YH; Wang J
J Control Release; 2016 Jun; 231():17-28. PubMed ID: 26829099
[TBL] [Abstract][Full Text] [Related]
35. Semi-Synthetic Ingenol Derivative from Euphorbia tirucalli Inhibits Protein Kinase C Isotypes and Promotes Autophagy and S-phase Arrest on Glioma Cell Lines.
Silva VAO; Rosa MN; Tansini A; Martinho O; Tanuri A; Evangelista AF; Cruvinel Carloni A; Lima JP; Pianowski LF; Reis RM
Molecules; 2019 Nov; 24(23):. PubMed ID: 31771098
[TBL] [Abstract][Full Text] [Related]
36. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy with dendritic cell vaccine and IL-2 encapsulating polymeric micelles enhances intra-tumoral accumulation of antigen-specific CTLs.
Miki K; Nagaoka K; Harada M; Hayashi T; Jinguji H; Kato Y; Maekawa R
Int Immunopharmacol; 2014 Dec; 23(2):499-504. PubMed ID: 25284343
[TBL] [Abstract][Full Text] [Related]
38. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors.
Tähtinen S; Kaikkonen S; Merisalo-Soikkeli M; Grönberg-Vähä-Koskela S; Kanerva A; Parviainen S; Vähä-Koskela M; Hemminki A
PLoS One; 2015; 10(6):e0131242. PubMed ID: 26107883
[TBL] [Abstract][Full Text] [Related]
39. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
[TBL] [Abstract][Full Text] [Related]
40. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.
Sabel MS; Arora A; Su G; Mathiowitz E; Reineke JJ; Chang AE
Surgery; 2007 Nov; 142(5):749-60. PubMed ID: 17981196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
